CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-26 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 | +7,472 | 37,521 | ||
| 2025-09-26 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 | −3,651 | $36.77 | $134K | 33,870 |
| 2025-09-26 | Jones Cecilia Chief Financial Officer | Option exercise · Restricted stock units 10b5-1 | −7,472 | 0 | ||
| 2025-09-05 | Washburn Theodore James Jr. Principal Accounting Officer | Sale | −8,546 | $36.87 | $315K | 868 |
| 2025-08-27 | Scadden David Director | Option exercise 10b5-1 | +200 | $18.09 | $4K | 17,803 |
| 2025-08-27 | Scadden David Director | Sale 10b5-1 | −200 | $40.00 | $8K | 17,603 |
| 2025-08-27 | Scadden David Director | Option exercise · Stock options (right to buy) 10b5-1 | −200 | 27,507 | ||
| 2025-08-11 | Ballal Rahul D. Director | Option exercise | +2,302 | 12,414 | ||
| 2025-08-11 | Ballal Rahul D. Director | Option exercise · Restricted stock units | −2,302 | 0 | ||
| 2025-08-11 | Smith Cynthia Director | Option exercise | +2,302 | 12,414 | ||
| 2025-08-11 | Smith Cynthia Director | Option exercise · Restricted stock units | −2,302 | 0 | ||
| 2025-08-08 | Goff Brian Chief Executive Officer | Option exercise 10b5-1 | +22,691 | 134,613 | ||
| 2025-08-08 | Goff Brian Chief Executive Officer | Sale 10b5-1 | −11,085 | $36.67 | $406K | 123,528 |
| 2025-08-08 | Goff Brian Chief Executive Officer | Option exercise · Restricted stock units 10b5-1 | −22,691 | 0 | ||
| 2025-07-10 | Scadden David Director | Option exercise 10b5-1 | +1,400 | $18.09 | $25K | 19,003 |
| 2025-07-10 | Scadden David Director | Sale 10b5-1 | −1,400 | $40.00 | $56K | 17,603 |
| 2025-07-10 | Scadden David Director | Option exercise · Stock options (right to buy) 10b5-1 | −1,400 | 27,707 | ||
| 2025-07-09 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 | +11,914 | $25.01 | $298K | 73,185 |
| 2025-07-09 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −11,067 | $37.93 | $420K | 62,118 |
| 2025-07-09 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 | −847 | $38.76 | $33K | 61,271 |
Page 11 of 48 · 941 trades